YILING PHARMACEUTICAL: Wholly-owned subsidiary Anastrozole raw material drug has received the approval notice for listing application

Zhitong
2025.10.29 08:19

YILING PHARMACEUTICAL announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, and the listing application for Anastrozole chemical raw materials has been approved. Anastrozole is a drug widely used in the treatment of estrogen-related tumors, especially in postmenopausal hormone receptor-positive female breast cancer patients. YILING PHARMACEUTICAL's wholly-owned subsidiary, Beijing Yiling Biotechnology Co., Ltd., holds the approval for Anastrozole tablet formulations, which are centralized procurement products, and it is expected that integrated production of raw materials and formulations can be achieved this year

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer